Duchenne 근디스트로피의 치료에 대한 고찰 = Treatment of Duchenne Muscular Dystrophy: A Comprehensive Review

다국어 초록 (Multilingual Abstract)

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder due to the loss of dystrophin in muscle fiber. The deficiency of dystrophin produces severe progressive muscle degeneration which leads to progressive muscle weakness.
Affected patients usually become unambulatory in their early teens, and suffer a respiratory failure before 20 years of age. In an attempt to improve quality of life and extend life span of DMD patients, various treatments have been challenged; corticosteroid trial, rehabilitation, cardiac and pulmonary managements, orthopedic interventions, and nutritional support. However, only corticosteroid therapy and non-invasive ventilation have shown a salutary effect on the clinical course of DMD. Recently, a better understanding of the DMD pathophysiology has provided the scientific basis for new treatment modalities including cell and molecular therapy. Although previous clinical trials have demonstrated the limitation and possibility of new therapies, antisense-mediated exon skipping technology is now emerging as a promising approach to restore dystrophin expression. This article summarizes the current challenges and recommendations of treatment approaches in DMD patients.

참고문헌 (Reference)

1 Miura P, "Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?" 12 : 122-129, 2006

2 Karpati G, "Utrophin muscles in on the action" 3 : 22-23, 1997

3 Ciafaloni E, "Treatment options for Duchenne muscular dystrophy" 10 : 86-93, 2008

4 Angelini C, "The role of corticosteroids in muscular dystrophy: a critical appraisal" 36 : 424-435, 2007

5 Bakker JP, "The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature" 14 : 343-359, 2000

6 Meng J, "The contribution of human synovial stem cells to skeletal muscle regeneration" 20 : 6-15, 2010

7 Bachrach E, "Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells" 101 : 3581-3586, 2004

8 Eagle M, "Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation" 12 : 926-929, 2002

9 Mesa LE, "Steroids in Duchenne muscular dystrophy--deflazacort trial" 1 : 261-266, 1991

10 Heller KD, "Spinal stabilization in Duchenne muscular dystrophy: principles of treatment and record of 31 operative treated cases" 10 : 18-24, 2001

11 Lee SJ, "Speed and endurance: you can have it all" 109 : 621-622, 2010

12 Li D, "Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin" 123 : 2008-2013, 2010

13 Benchaouir R, "Restoration of human dystrophin followingtransplantation of exon-skipping-engineered DMD patient stem cellsinto dystrophic mice" 1 : 646-657, 2007

14 Eagle M., "Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002" 12 : 975-983, 2002

15 Renault V, "Regenerative potential of human skeletal muscle during aging" 1 : 132-139, 2002

16 Mizuno Y, "Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects" 119 : 43-52, 1993

17 Mendell JR, "Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy" 320 : 1592-1597, 1989

18 Griggs RC, "Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group" 48 : 383-388, 1991

19 Moxley RT 3rd, "Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society" 64 : 13-20, 2005

20 Velasco MV, "Posterior spinal fusion for scoliosis in duchenne muscular dystrophy diminishes the rate of respiratory decline" 32 : 459-465, 2007

21 Emery AE., "Population frequencies of inherited neuromuscular diseases--a world survey" 1 : 19-29, 1991

22 Romero NB, "Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy" 15 : 1065-1076, 2004

23 Dellavalle A, "Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells" 9 : 255-267, 2007

24 Gussoni E, "Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation" 356 : 435-438, 1992

25 Wolff J, "Non-viral approaches for gene transfer" 24 : 202-208, 2005

26 Bogdanovich S, "Myostatin propeptide-mediated amelioration of dystrophic pathophysiology" 19 : 543-549, 2005

27 Mendell JR, "Myoblast transfer in the treatment of Duchenne's muscular dystrophy" 333 : 832-838, 1995

28 Sampaolesi M, "Mesoangioblast stem cells ameliorate musclefunction in dystrophic dogs" 444 : 574-579, 2006

29 Ichim TE, "Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy" 260 : 75-82, 2010

30 Wagner KR, "Loss of myostatin attenuates severity of muscular dystrophy in mdx mice" 52 : 832-836, 2002

31 Gussoni E, "Long-term persistence of donor nuclei in a Duchennemuscular dystrophy patient receiving bone marrow transplantation" 110 : 807-814, 2002

32 Biggar WD, "Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade" 16 : 249-255, 2006

33 van Deutekom JC, "Local dystrophin restoration with antisense oligonucleotide PRO051" 357 : 2677-2686, 2007

34 McDonald CM, "Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery" 9 : 187-211, 1998

35 Moens PD, "Lack of myoblasts migration between transplanted and host muscles of mdx and normal mice" 17 : 37-43, 1996

36 Mir LM, "High-efficiency gene transfer into skeletal muscle mediated by electric pulses" 96 : 4262-4267, 1999

37 Huard J, "High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice" 93 : 586-599, 1994

38 Dell'Agnola C, "Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs" 104 : 4311-4318, 2004

39 Wagner KR, "Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations" 49 : 706-711, 2001

40 Dunant P, "Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle" 27 : 624-627, 2003

41 Mizuno Y, "Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells" 24 : 2245-2253, 2010

42 Chapdelaine P, "Functional EGFP-dystrophin fusion proteins for gene therapy vector development" 13 : 611-615, 2000

43 Tinsley J, "Expression of full-length utrophin prevents muscular dystrophy in mdx mice" 4 : 1441-1444, 1998

44 Gissel H, "Excitation-induced Ca2+ influx and skeletal muscle cell damage" 171 : 327-334, 2001

45 Heslop L, "Evidence for a myogenic stem cell that is exhausted in dystrophic muscle" 113 (113): 2299-2308, 2000

46 Darabi R, "Engraftment of embryonic stem cell-derived myogenic progenitors in a dominant model of muscular dystrophy" 220 : 212-216, 2009

47 Pichavant C, "Electrotransfer of the full-length dog dystrophin into mouse and dystrophic dog muscles" 21 : 1591-1601, 2010

48 Mendell JR, "Dystrophin immunity in Duchenne's muscular dystrophy" 363 : 1429-1437, 2010

49 Beauchamp JR, "Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source" 144 : 1113-1122, 1999

50 Sussman M., "Duchenne muscular dystrophy" 10 : 138-151, 2002

51 Sinnreich M., "Disorders of voluntary muscle" Cambridge University Press 205-229, 2009

52 Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management" 9 : 77-93, 2010

53 Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care" 9 : 177-189, 2010

54 Houde S, "Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up" 38 : 200-206, 2008

55 Biggar WD, "Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols" 14 : 476-482, 2004

56 Pichavant C, "Current status of pharmaceutical and genetic therapeutic approaches to treat DMD" 19 : 830-840, 2011

57 Markham LW, "Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy" 18 : 365-370, 2008

58 Koenig M, "Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals" 50 : 509-517, 1987

59 Florence JM, "Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures" 64 : 41-45, 1984

60 Brooke MH, "Clinical trial in Duchenne dystrophy" 4 : 186-197, 1981

61 American Academy of Pediatrics Section on Cardiology and Cardiac Surgery, "Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy" 116 : 1569-1573, 2005

62 Escolar DM, "CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy" 58 (58): 151-155, 2005

63 Dezawa M, "Bone marrow stromal cells generate muscle cells and repair muscle degeneration" 309 : 314-317, 2005

64 Dias N, "Antisense oligonucleotides: basic concepts and mechanisms" 1 : 347-355, 2002

65 Adams AM, "Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries" 8 : 57-, 2007

66 Barton-Davis ER, "Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice" 104 : 375-381, 1999

67 Manuvakhova M, "Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system" 6 : 1044-1055, 2000

68 Hyde SA, "A randomized comparative study of two methods for controlling Tendo Achilles contracture in Duchenne muscular dystrophy" 10 : 2000

69 Wagner KR, "A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy" 63 : 561-571, 2008

70 Wang B, "A canine minidystrophin is functional and therapeutic in mdx mice" 15 : 1099-1106, 2008

71 Bushby K, "107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy" 13 : 166-172, 2003